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Reduced proximal tubule angiotensin II receptor expression in strep-
tozotocin-induced diabetes mellitus. Diabetes mellitus is characterized by
alterations in the intrarenal renin-angiotensin system, including decreases
in glomerular angiotensin II (Ang II) receptor density. Since Ang II
regulates proximal tubule transport function, the present studies examined
whether diabetes altered expression of proximal tubule receptors. In
basolateral membranes from 14 day streptozotocin-induced diabetic rats,
specific binding of 1251 Ang II was decreased to 53 8% of control (3.2
0.5 vs. 1.5 0.2 fmol/mg protein; N = 7; P < 0.02). Similarly, in proximal
tubule brush border membranes from diabetic animals, specific binding
was decreased to 63 11% of control (1.1 0.2 vs. 0.6 0.1 fmol/mg
protein; N = 9; P < 0.05). Concomitant insulin treatment reversed the
decrease in specific binding of 1251 Ang II to basolateral membranes (109
26% of control; N = 3) and to brush border membranes (85 17% of
control; N = 6). In order to determine if changes in expression of type-i
Ang II receptors (AT1R) accompanied the changes in binding, quantita-
tive polymerase chain reaction of AT1R mRNA was performed and
expressed as the ratio of the amplified AT1R to that of an Mscl/Mscl
internal deletion mutant and normalized to that of (3-actin. In total RNA
from proximal tubule suspensions of diabetic animals, AT1R mRNA
expression decreased by 38% (21 3 vs. 13 2 cpm AT1R/cpm deletion
mutant/cpm /3 actin/106; N = 4; P < 0.0025). Insulin treatment reverted
AT1R mRNA expression to control levels (22 3 cpm AT1R/cpm
deletion mutant/cpm /3 actin/106; P < 0.001 compared to the untreated
group). Since both AT1aR and AT1bR exist in rat kidney, restriction
digests of the PCR-amplified products were performed with Hae III,
which indicated the presence of both subtypes in rat proximal tubule.
Expression of both subtypes decreased in diabetic rats. Therefore, in rats
with untreated streptozotocin-induced diabetes, both proximal tubule Ang
II binding and AT1R mRNA levels decrease. Insulin treatment reverses
these abnormalities, These findings suggest that, similar to glomeruli, the
diabetic milieu leads to decreased expression of proximal Ang II recep-
tors. This defect in receptor expression may contribute to abnormalities in
volume regulation and acid/base balance in diabetes.
In the mammalian proximal tubule, angiotensin II (Ang II) is an
important regulator of NaC1, NaHCO3 and net volume reabsorp-
tion [1]. In addition, Ang II regulates other metabolic functions of
this nephron segment and may be a mediator of hypertrophic
;rowth [2]. All of the components of the renin-angiotensin system
have been localized to the mammalian proximal tubule [3—5], and
it has been suggested that local as well as systemic regulation of
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the renin-angiotensin system is involved in the mediation of
proximal tubule reabsorption.
The actions of Ang II in the proximal tubule are mediated by
specific Ang II receptors, present on both apical and basolateral
membranes. Recent studies have indicated that in both rat and
rabbit, binding of 1251 Ang II to either basolateral or brush border
membranes is completely inhibited by the type 1 receptor antag-
onist, losartan, indicating that in proximal tubule, the Ang II
receptors are type 1 receptors (AT1R) [6]. Alterations in Ang II
receptor density in the proximal tubule may occur as a physiologic
response to changes in intravascular volume [7] and may be
involved in pathophysiologic states such as in the prehypertensive
spontaneously hypertensive rat [8].
Ang II receptor binding in the glomerulus is decreased in
experimentally induced diabetes [9, 10]. The functional signifi-
cance of this decrease in receptors is not clear, since studies have
indicated that administration of losartan to streptozotocin-in-
duced diabetic rats caused decreases in intraglomerular capillary
pressure and increases in Kf [11]. In contrast, losartan did not
alter proximal tubule reabsorption in diabetic rats [11], although
administration of this inhibitor to normal rats produced significant
natriuresis and diuresis [12]. These findings suggest that in
diabetes, proximal tubules may have decreased responsiveness to
Ang II. The present studies were designed to examine whether
proximal tubule Ang II receptor density is altered in diabetes. The
results indicate that animals with untreated diabetes manifest a
significant decrease in expression of AT1R mRNA, which is
associated with decreases in both basolateral and brush border
1251 Ang II binding.
Methods
Animals
Diabetes was induced in male Sprague-Dawley rats (200 to 250
g) by a single intravenous injection of streptozotocin (60 mg/kg),
as previously described [13}. Only animals that had documented
hyperglycemia and glycosuria 24 hours after injection were used.
The insulin-treated subgroup received a daily subcutaneous injec-
tion of 2 U ultralente insulin/100 g body weight (Eli Lilly,
Indianapolis, Indiana, USA) daily, beginning 24 hours after
streptozotocin administration. Preliminary studies suggested that
this dose provided glycemic control (minimal glycosuria). Animals
were sacrificed two weeks after the institution of diabetes. For
membrane preparation and RNA extraction, each "N" is derived
from tissue pooled from three to four animals.
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Renin assays
Plasma and tissue renin activity were measured by radioimmu-
noassay using previously published methods [111. Animals were
subjected to ether anesthesia prior to collection of blood or
organs. For tissue preparation, kidneys were homogenized in 0.1
M Tris-HC1 pH 7.4, containing 0.25 mi EDTA and 0.1% Triton
X-100, then centrifuged at 10,000 g at 4°C.
Preparation of membranes and isolated nephron segments
Renal cortical membranes were prepared as previously de-
scribed [13, 14] with protein concentrations measured using the
method of Lowry et al [15]. As we have previously described,
BLM were enriched in ouabain-sensitive Na-K ATPase activity
by 7- to 11-fold, while BBM had no significant enrichment in this
enzyme. That the relative purification of BLM from the different
experimental groups was not different was indicated by demon-
stration of similar ouabain-sensitive Na-K ATPase activity in
the BLM preparations [control 29.6 4.8 nmol/mg protein/mm
(N 5); untreated diabetes 26.9 3.8 nmol/mg protein/mm (N =
5); insulin-treated diabetic 19.5 4.8 nmollmg protein/mm (N =
3)]. BBM exhibited a —6- to 8-fold increase in alkaline phos-
phatase activity, while BLM did not have increased activity [6, 13].
Similar relative purification among experimental groups was
indicated by similar alkaline phosphatase activity in BBM [control
0.70 0.24 tmol/mg protein/mm (N = 4); untreated diabetes
0.62 0.21 xmol/mg protein/mm (N = 7); insulin-treated diabe-
tes 0.52 0.17 jimollmg protein/mm (N =5)]. For preparation of
suspensions of proximal tubules, modifications of the method of
Vinay et al [16] were used as previously described [14].
Binding to kidney cortical membranes
Binding assays were performed using 125JAng II as previously
described [6]. Briefly, membranes (50 to 150 tg) were incubated
at room temperature in a solution of 100 mtvi NaC1, 5 mM
ethylenediaminetetraacetate, 10 mM HEPES (pH 7.5), 100 mvt
mannitol, 0.5% bovine serum albumin, 0.1 m MgSO4, 0.5%
trypsin inhibitor, 0.005% aprotinin, 0.1 mii phenylmethylsulfon-
ylfluoride and 0.1 nvi 1251-labeled Ang II. Under these conditions,
equilibrium binding occurred within 10 to 15 minutes for both
BLM and BBM preparations. Binding was routinely terminated
after 20 minutes by addition of 2 ml of ice-cold stop solution [300
mM NaCl, 10 mM Tris (pH 7.5), 100 m'vi mannitol, 50 mM MgCl2],
followed immediately by rapid filtration through presoaked 0.65
jm filters (DAWP; Millipore Corp., Bedford, Massachusetts,
USA) and four washes with 2 ml each of stop solution, Radioac-
tivity bound to the filters was counted in a gamma counter.
Specific binding was determined as total binding minus nonspe-
cific binding in the presence of excess unlabeled Ang 11(10—6 M).
For binding curves, the amount of specific binding (total-nonspe-
cific) was determined in the presence of 0.1 nM 1251 labeled Mg
II and increasing concentrations of unlabeled Mg II.
Quantitative polymerase chain reaction (PCR) ofAT1 receptor
Total RNA was isolated by the acid guanidinium thiocyanate-
phenol-chloroform method [17]. As an internal control for quan-
titative PCR, a deletion mutant was constructed by cutting rabbit
AT1R clone 3 [6] with MscI (which cuts at two sites in this clone,
304 and 593) and religating. The mutant plasmid was then
linearized and used as a template for RNA transcription. For
PCR, total RNA (10 g) and deletion mutant AT1R RNA (200
pg) were mixed and reverse transcribed using murine reverse
transcriptase (Pharmacia, First Strand eDNA Synthesis kit, Pisca-
taway, New Jersey, USA) and a primer specific for the AT1R. The
resultant single strand cDNA mixture was then amplified in a
Perkin Elmer GeneAMP 9600 PCR System using Taq polymerase
(Perkin Elmer/Cetus). Samples were amplified in the presence of
32p CTP (New England Nuclear, Boston, Massachusetts, USA;
3000 Ci • mmol; 2 jtCi/sample). Preliminary studies determined
linearity of response for at least 40 cycles for both intact receptor
and deletion fragment, and PCR was routinely carried out for 35
cycles at 95°C for 20 seconds, 55°C for 30 seconds and 72°C for 90
seconds, followed by a 10 minutes extension at 72°C. The em-
ployed primers were upstream sense primer, 5'-TGGGAATATT-
TGGGAACAGC-3' and downstream anti-sense primer, 3'-GT-
GAATATTTGGTGGGGAAC-5'. Amplification of intact and
mutant AT1R mRNA by these primers yielded 703 bp and 415 bp
fragments, respectively. No amplification occurred in the absence
of reverse transcription, indicating that genomic DNA was not
being amplified. In preliminary experiments, samples of cortex
from normal rat cortex and proximal tubule were reverse tran-
scribed and amplified in the presence of the deletion fragment
(and in the absence of a-32P CTP), transferred to nylon mem-
branes and hybridized with a cDNA of rabbit AT1R containing
the complete coding region that was labeled by the random
priming method to >108 cpm/tg. Hybrization to the amplified 703
bp and 415 bp fragments was observed. For normalization,
parallel samples measured amplification of 13-actin cDNA using
the primers, 5 '-AACCGCGAGAAGATGACCCAGATCAT-
GTTT-3'; and 3' -AGCAGCCGTGGCCATCTCTTGCTC-
UAAGTC-5' [18]. Preliminary studies indicated linearity of
/3-actin mRNA amplification for >40 cycles. Following gel chro-
matography on 4% agarose gels, the bands corresponding to the
PCR products from intact AT1R, the deletion fragment and
/3-actin were excised and the radioactivity determined by scintil-
lation spectrometly. Results are represented as the ratio of intact
and deletion fragment AT1R mRNA amplified, normalized to the
amount of amplified 13-actin mRNA. This method provides a
relative comparison of the amount of AT1R mRNA present
among the different experimental groups.
Statistics
Results are presented as the means SEM. For statistical
analysis, Student's unpaired t-test was employed. For multiple
group comparisons, ANOVA and the Bonferroni/Dunn t-test
were utilized, with P < 0.05 indicating significance.
Results
The rats with streptozotocin-induced diabetes evidenced severe
hyperglycemia, as well as glycosuria and mild ketonuria (Table 1).
In these rats, there were significant decreases in body weight and
increases in the kidney weight/body weight ratio two weeks after
induction of diabetes (Table 1). Insulin treatment partially re-
versed the decreases in body weight, as well as the renal hyper-
trophy (Table 1). In the diabetic animals not receiving insulin,
plasma renin levels were significantly decreased compared to
controls [3.9 1.2 (N = 8) vs. 8.4 1.0 ng/ml/hr (N = 6); P <
0.05). Renal tissue renin was not significantly different between
control and untreated diabetic animals (control 0.17 0.04 vs.
0.18 0.03 ng/hr/mg protein; N = 6). In the insulin-treated
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Table 1. Physiologic parameters in streptozotocin-induced diabetes mellitus
Body
weight
g
Kidney
weight
. .
Kidney weight
body weight
%
Plasma
glucose
mg/di
.Urine
volume
mi/day
.Urine
glucose
mg/di
Plasma
renin
ng/ml/hr
Kidney renin
ngfhr/mgprotein
Control
x 359 1.36 0.38 90 17 0 8.3 0.17
SEM 9 0.04 0.01 6 1 1.0 0.04
(N) (11) (11) (11) (10) (11) (11) (6) (6)
Untreated diabetic
x 229C 1.27 0.57c 329 86C >500 3•9a 0.18
SEM 15 0.08 0.01 17 3 1.2 0.03
(N) (12) (12) (12) (11) (12) (12) (8) (5)
Insulin-treated diabetic
X 261b 1.13 0.44a 158C 39b 125—250 5.4 0.49
SEM 26 0.09 0.02 11 8 2.0 0.17
(N) (9) (9) (9) (8) (9) (9) (7) (4)
Results of urine glucose measurements represent semi-quantitative results of urine dipstick analysis. Note that in the untreated diabetic group, all
urine glucoses tested >500.
a P < 0.05 compared to control
b P < 0.01 compared to control
CP < 0.001 compared to control
subgroup, plasma renin levels were intermediate between the
control and diabetic groups (5.4 2.0 ng/hr/mg; N = 6), while
renal tissue renin was numerically but not significantly higher than
control (0.49 0.17 ng/hr/mg).
To determine whether proximal tubule Ang II receptor density
was altered by diabetes, 1251 Ang II binding was performed on
both basolateral and brush border membranes from control,
diabetic and insulin-treated diabetic rats. In basolateral mem-
branes from diabetic rats, specific binding of 125J Ang II was
decreased to 53 8% of control (3.2 0.5 vs. 1.5 0.2 fmol/mg
protein; N = 7; P < 0.02; Fig. 1A). The decrease was due to a
reduction in the number of binding sites (Bm control: 103
fmol/mg protein; diabetic: 35 fmol/mg protein) without alteration
in the binding affinity, Kd (4.68 vs. 3.17 nM; Fig. 1B). Similarly, in
brush border membranes from untreated diabetic animals specific
binding of 125J Aug11 decreased to 63 11% of control (1.1 0.2
vs. 0.6 0.1 fmol/mg protein; N = 9; P < 0.05; Fig. 1C). As with
basolateral membranes, there was a decrease in binding sites in
the brush border membranes from the untreated diabetics (Bm
control 32 fmol/mg protein; diabetic 16 fmol/mg protein; Kd
control 3.7; diabetic 3.8 nM; Fig. 1D). The AT1R-specific inhibitor,
losartan (10—v M) inhibited specific Aug II binding to both control
and diabetic basolateral membranes (percent inhibition: 96 4%
and 100 0% respectively; N = 3) and brush border membranes(percent inhibition: 94 6% and 99 1%, respectively; N 7).
In a subset of animals, insulin treatment reversed the decrease in
specific binding of Ang II to basolateral membranes (Fig. 2A;
control 2.43 0.52 fmol/mg protein; untreated diabetic 1.47
0.38 fmol/mg protein; insulin-treated diabetic 2.40 0.06 fmol/mg
protein; N = 3) and brush border membranes (Fig. 2B; control
0.85 0.21 fmol/mg protein; untreated diabetic 0.48 0.06
fmol/mg protein; insulin-treated diabetic 0.65 0.15 fmol/mg
protein; N = 6).
In preliminary experiments Northern analysis of total RNA
suggested decreases in message abundance for AT1R mRNA in
proximal tubule of diabetic rats. To quantify alterations in AT1R
mRNA expression, quantitative PCR was performed (Fig. 3A and
Table 2). The results were normalized to amplification of -actin
mRNA, as discussed in the Methods. In preliminary experiments,
it was determined that the amount of f3-actin mRNA present in
varying concentrations of total RNA from proximal tubules was
not different among the groups. Also, as indicated in Table 2,
there were no differences within experiments of -actin mRNA
among the groups. In the untreated diabetic animals, AT1R
mRNA expression was decreased 38% (20.8 1.4 vs. 12.7 1.1
cpm AT1R/deletion mutant/-actinh106; N = 4; P < 0.0025).
Insulin treatment reverted AT1R mRNA expression to control
levels (23.3 1.8; N = 4; P < 0.001 compared to the untreated
group; Table 2, Fig. 3B).
Rats express two different isoforms of AT1R, namely AT1aR
and AT1bR [19]. These isoforms, which have 96% amino acid
identity, are products of two different genes and are differentally
expressed in various tissues [19]. mRNA for both AT1aR and
AT1bR are found in rat kidney, but no previous studies have
determined which subtype(s) is present in proximal tubule. The
primers used for PCR in the present experiments amplify both
AT1aR and AT1bR. In order to determine which subtypes were
present on proximal tubule and whether the decrease in AT1R
mRNA represented selective loss of one subtype, PCR was
performed on total RNA from proximal tubules of control and
diabetic animals and then digested with the restriction endonu-
clease, Hae III. Hae Ill digestion of the 703 bp PCR product of
AT1aR generates fragments of 194, 112, 110, 95, 69,48, 42 and 33
bp, while digestion of AT1bR generates fragments of 304, 110,
103, 95 and 91 bp. Adrenal expresses predominantly AT1bR
mRNA, as shown in Figure 4A, while glomeruli express predom-
inantly AT1aR (data not shown). As can be seen in Figure 4B,
proximal tubule contains both AT1aR and ATSbR messages (note
that both 304 and 194 bp fragments are detected). In three
separate experiments, RNA from proximal tubules of untreated
diabetic animals exhibited apparent decreases in message levels of
both AT1aR and AT1bR (Fig. 4B). Although these results do not
provide quantitative comparison of alterations in AT1aR and
AT1bR mRNA expression in diabetes, they suggest that the
decreases in 125J Aug II binding are not the result of selective
decrease in only one subtype.
Fig. 1. A. Decreased Ang II binding in
basolateral membranes from diabetic rats.
Representation of 0.1 nM 1251 Ang II
specifically bound. N = 7; ** < 0.02. (B).
Scatchard analysis of specific binding of 'I
Ang II in control and diabetic basolateral
membranes as a function of 125J Ang II
concentration. Results represent mean values of
7 separate binding experiments. Symbols are:
control (0; Bma,, 103 fmol/mg protein; Kd 4.68
flM) diabetes (•); Bm 35 fmol/mg protein, lCd
3.17 nM). (C) Decreased Mg II binding in
brush border membranes from diabetic rats.
Representation of amount of 0.1 nM 1251 Ang II
specifically bound (N = 9; P < 0.05). (D
Scatchard analysis of specific binding of 1
Mg II in control and diabetic brush border
membranes as a function of 1I Mg II
concentration. Results represent mean values of
9 separate binding experiments. Symbols are:
control (0; Bm 32 fmollmg protein, K. 3.7
nM); diabetes (•; Bm,, 16 fmol/mg protein; 1d
3.8 flM).
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Fig. 2. A. Insulin treatment reverses decreased basolateral membrane Ang II
binding in diabetes. (N) = control: (7); diabetic: (7); insulin treated
diabetic: (3). *P < 0.05. (B) Insulin treatment reverses decreased brush
border membrane Ang II binding in diabetes. (IV) = control: (9); diabetic:
(9); insulin treated diabetic: (7); * < 0.05.
Discussion
The present studies indicate that untreated diabetic rats had
decreased steady state levels of AT1R mRNA and manifested
decreased AT1 receptor density on both basolateral and brush
border membranes. Treatment with insulin reverted both AT1R
Fig. 3. A. RT-PCR amplification of ATJR mRNA in renal cortex and
proximal tubules from diabetic rats. Two hundred picograms of cRNA of an
MscI/MscI deletion fragment of rabbit AT1R was mixed with 10 g of total
RNA from either renal cortex or proximal tubules and reversed tran-
scribed. Following reverse transcription, PCR was carried out for 35 cycles
at 95°C for 20 seconds, 55°C for 30 seconds and 72°C for 90 seconds using
5'-TGGGAATA1TFGGGAACAGC-3' as the upstream sense primer
and 3'-GTGAATATTTGGTGGGGAAC-S' as the downstream antisense
primer. The amplified fragment of intact AT1R is 703 bp and the
MscI/MscI deletion is 415 bp. lane 1: control cortex; lane 2: untreated
diabetic cortex; lane 3: insulin-treated diabetic; lane 4: control proximal
tubules; lane 5: untreated diabetic proximal tubules; lane 6: size markers
(HAF III Digest of PhiX 174 RF DNA). (B) Insulin treatment reverses
the decreased AT1R mRNA expression in proximal tubule in diabetes.
Quantitative PCR results from total RNA from proximal tubule suspen-
sions from 4 separate experiments. Results of individual experiments are
provided in Table 2 * < 0.0025 compared to control; #P < 0.001
compared to insulin treatment.
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Table 2. Quantitative polymcrase chain reaction amplification of AT1R mRNA from proximal tubule suspensions
AT1R/deletion mutant/f3-actin/106(cpm/cpm/cpm)
DiabetesExperiment Control Insulin treatment
1 24.6 (3958/6327/25439) 12.7 (2662/13979/15019) 263 (4996/9644/19693)
2 19.8 (2870/3478/41651) 10.6 (1163/2172/50539) 19.3 (1977/3020/33859)
3 20.9 (3591/3468/49546) 15.7 (1889/2559/46928) 26.5 (3767/3020/47077)
4 17.8 (26110/18207/80424) 11.7 (2724/3239/72003) 20.9 (29776/19589/72721)
x 20.8 1.4 12.7 iS 233 1.8
Results of quantitative PCR from total RNA from proximal tubule suspensions of four separate experiments. The studies were performed as described
in Figure 4. Results in bold represent the ratio of the cpm of 32P CTP incorporated in AT1RJcpm incorporated into the deletion mutant/cpm
incorporated into Ø-actin/106, The cpm of each experiment are provided in parentheses.
aP < 0.0025 compared to control; P < 0.001 compared to insulin treatment
message level and receptor density toward control levels. These
studies indicate that that the diabetic state decreased the level of
message expression of AT1R.
The mechanism by which diabetes altered Ang II receptor
density in the proximal tubule has not been determined. Wilkes et
al have indicated that in glomeruli, untreated diabetes may lead to
a generalized decrease in vasoconstrictor receptors [20]. Williams,
Tsai and Schrier have reported that in cultured rat aortic smooth
muscle cells, both Ang II and vasopression receptors decrease
when cells are grown in a high glucose medium [21]. This decrease
in receptor density appears to be mediated by protein kinase C, a
finding of interest since elevated glomerular protein kinase C
levels have been reported in glomeruli from streptozotocin-
induced diabetic rats [22]. However, in cultured rat mesangial
cells, protein kinase C activation did not appear to be involved in
down-regulation of steady state AT1R mRNA levels [23]. In the
present studies, the decreased Ang II binding correlated with an
decrease in steady state AT1R mRNA levels in diabetic tubules.
Whether these differences in mRNA levels reflect inhibition of
transcription and/or decreased message stability was not ad-
dressed in the present studies and will be the subject of further
investigation.
In contrast to the present studies, Wolf et al have reported that
cultured mouse proximal tubule cells grown in culture medium
containing 450 mg/dl glucose have increased 1251 Ang II binding
compared to cells grown in 100 mg/dl glucose [24]. Therefore, the
observed decreases in AT1R receptor density observed in vivo
may be the result of other alterations in the diabetic milieu instead
of (or in addition to) hyperglycemia per se. In this regard, chronic
insulin treatment increased 1251 Ang II binding in cultured rat
mesangial cells [25].
Of interest, in the diabetic animals, plasma renin levels were
significantly decreased compared to control animals, and insulin
treatment also led to partial correction. Our findings of decreased
plasma renin activity in untreated streptozotocin diabetic rats is
consistent with previous studies in rats [26—29] and humans [30,
31]. Such studies have indicated that exchangable sodium is
increased 10 to 25%, indicating relative volume expansion [28,
30]. In other studies in untreated streptozotocin diabetic rats,
renal renin mRNA [26] and tissue renin activity [32] have been
reported to be decreased, nlthough in the present studies, no
difference in tissue renin activity was noted. When diabetic
animals are kept in moderate glycemic control, renal tissue renin
activity and mRNA have been reported to be either increased [9]
or unchanged [33].
Micropuncture studies have shown that treatment with losartan
decreased intraglomerular pressure and increased Kf in poorly
controlled diabetes [9]. Indeed, Anderson, Jung and Ingelfinger
have suggested that activity of the intrarenal renin-angiotensin
system may be increased in such animals, and that there is a
specific increase in glomerular angiotensin II production, as
suggested by a selective increase in glomerular angiotensin con-
verting enzyme activity [11]. Therefore, it is possible that the
recognized decreases in glomerular Ang II binding in untreated
streptozotocin-induced diabetes [10, 11] may be secondary to
increased local levels of Ang II, since it has been shown that
glomerular Ang II binding is decreased in states of increased
circulating angiotensin II [34]. Furthermore, in cultured mesan-
gial and smooth muscle cells, angiotensin II administration de-
creases AT1R mRNA levels [23, 35].
No previous studies have examined Ang II binding in proximal
tubule cells from diabetic animals. However, Anderson et al found
that treatment of diabetic rats with losartan did not alter urine
volume or electrolyte excretion [11], in contradistinction to the
dramatic inhibition of proximal tubule function seen following
losartan infusion in normal rats [10]. These studies suggest
decreased local proximal tubule angiotensin II production and/or
decreased proximal tubule responsiveness to ambient angiotensin
II. Of interest, in diabetic rats, proximal tubule angiotensin
converting enzyme activity is significantly decreased compared to
controls [9].
In other studies from our laboratory, we have recently deter-
mined that in rabbit proximal tubules, AT1R mRNA and Ang II
binding decrease in response to captopril treatment and increase
in response to a low sodium diet [36]. Similar alterations in Ang II
binding have been reported in basolateral membranes from rats
[37]. Therefore, decreases in circulating and/or local proximal
tubule angiotensin II levels in diabetes may be reflected in
decreased AT1 receptors in the proximal tubule of these animals.
However, it is also possible that other alterations in the diabetic
state, such as insulin deficiency or corticosteroid excess [38] may
contribute to the decreases in Ang II receptors.
In the present studies, the 1d values for Ang II binding are
similar to what has been previously described in rat proximal
tubule brush border and basolateral membranes [7]. However, the
Bm values are lower than reported values [7]. The reason for this
discrepancy is not apparent; however, since the relative enrich-
ment and marker enzyme activity was similar in all experimental
groups, observed differences in relative binding among the groups
are meaningful.
The methods used for analysis of AT1R levels by PCR allow
quantitative comparison of expression of message levels among
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4— 304
e—194
110
4-304
4-194
4110
(—69
t- 69
1 2
Cheng et al: Receptor expression in diabetes 1609
deletion fragment of AT1R mRNA, by virtue of its smaller size,
was transcribed and/or amplified more efficiently than the intact
AT1R mRNA, the same amount of deletion fragment mRNA was
added to each sample, so that relative differences in the amount of
AT1R that were amplified were not affected.
The physiologic significance of decreased proximal tubule Ang
II receptors in diabetes has not yet been determined. Although
there is increased proximal reabsorption in the poorly controlled
diabetic state, Kumar, Gupta and Spitzer have suggested that this
increased reabsorption is due to increased glucose reabsorption
occurring with hyperglycemia [39]. In this regard, humans with
diabetes mellitus excrete more sodium following institution of
sodium restriction than do normal controls because they require
longer to reach a new homeostasis between intake and excretion
[40]. Whether a defect in proximal reabsorption may manifest
itself in the presence of acute volume depletion or angiotensin II
infusion must be defined with further studies.
Angiotensin II has also been shown to stimulate proximal
tubule ammoniagenesis [41], and it has been suggested that Ang II
is an important regulator of proximal tubule acid-base metabolism
[42]. It is possible that in association with hyperkalemia, de-
creased responsiveness to angiotensin II may partially underlie
the defect in ammonium secretion that leads to the devolopment
of the type IV renal tubular acidosis that is so common in the
diabetic population.
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Fig. 4. Expression of AT1R subtypes. Following RT-PCR, the 703 bp
fragment was digested with Hae Ill. Hae HI digestion of ATIaR provides
fragments of 194, 112, 110, 95, 69, 48, 42 and 33 bp, while digestion of
AT1bR provides fragments of 304, 110, 103, 95 and 91 bp. (A) Rat adrenal
expresses predominatly AT1bR. lane 1: size markers (HAE HI Digest of
PhiX 174 RF DNA); lane 2: control adrenal (B) Proximal tubules express
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